doxycycline

(redirected from Periostat)
Also found in: Thesaurus, Medical, Wikipedia.
Related to Periostat: doxycycline, Atridox

dox·y·cy·cline

 (dŏk′sĭ-sī′klēn′, -klĭn)
n.
A broad-spectrum antibiotic, C22H24N2O8, derived from tetracycline.

doxycycline

(ˌdɒksɪˈsaɪklɪn)
n
1. (Medicine) a tetracycline antibiotic used to treat conditions caused by a wide range of bacteria, including anthrax
2. (Pharmacology) a tetracycline antibiotic used to treat conditions caused by a wide range of bacteria, including anthrax
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.doxycycline - an antibiotic derived from tetracycline that is effective against many infections; "Vibramycin is the trade name of doxycycline"
antibiotic, antibiotic drug - a chemical substance derivable from a mold or bacterium that can kill microorganisms and cure bacterial infections; "when antibiotics were first discovered they were called wonder drugs"
Translations
doxycyklin

doxycycline

n doxiciclina
References in periodicals archive ?
Fowler is on the speakers' bureau for CollaGenex, which markets Periostat.
An open-label study and two ongoing studies funded by CollaGenex indicate that Periostat can treat and manage the symptoms of rosacea.
The third condition under investigation with Periostat is perioral dermatitis, which is also known as steroid withdrawal dermatitis.
Fowler estimated that FDA approval of new indications for Periostat might come in 2004.
Purpose: This study was designed to determine how widespread the use of Periostat is in the dental office.
Methods: A questionnaire was mailed to 100 randomly selected Nebraska dentists to collect data on the use of Periostat, results observed after using the product, and reasons for not using the product.
2 million of Periostat net sales, $128,000 in contract revenues and $100,000 in licensing fees.
5 million in net sales of Periostat and $650,000 of contract revenues.
2 million for the third quarter of 1999, which represented a 31% increase over Periostat net sales in the second quarter of 1999.
CollaGenex also currently sells Periostat, which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy periodontal support tissues and by enhancing bone protein synthesis, and Atridox(R), Atrisorb FreeFlow(R) and Atrisorb-D FreeFlow(R), which are products of QLT Inc.